This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups: \- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months. \- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months. \- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
66
1000 mg diosmin once daily for 3 months
100 mg rebamipide three times daily for 3 months
conventional medical treatment for RA
Faculty of Pharmacy Tanta University
Tanta, Egypt
RECRUITINGThe change in Disease Activity score-CRP (DAS28-CRP)
disease activity will be assessed through: Calculation of 28-joint count Disease Activity Score (DAS28) using C- reactive protein level (CRP) according to the following formula: DAS28-CRP = \[0.56\*√ (tender joint count) + 0.28\*√ (swollen joint count) + 0.36\*ln (CRP+1)\]\*1.10 + 1.15\]
Time frame: At baseline and after three months of the intervention
The change in The Health Assessment Questionnaire-Disability Index (HAQ-DI) score
the functional status of the participants will be assessed through: The Health Assessment Questionnaire-Disability Index (HAQ-DI)
Time frame: At baseline and after three months of the intervention
The change in serum level of C- reactive protein (CRP)
Time frame: three months
The change in serum level of Tumor necrosis factor-alpha (TNF-α)
Time frame: three months
The change in serum level of Matrix metalloproteinase-3 (MMP-3)
Time frame: three months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.